重磅！礼来“替尔泊肽”又一适应症在华获批

Insight数据库2025-07-03

7 月 3 日，NMPA 官网显示，礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究，Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报，扫描文末二维码添加小音，即可免费下载。截图来源：NMPA 官网替尔泊肽（Tirzepatide，穆峰达®）是代谢领域的重磅炸弹药物。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548534875?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-03 15:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548534875","market":"us","top_or_hot":-1,"title":"重磅！礼来“替尔泊肽”又一适应症在华获批","media":"Insight数据库","content":"<div>\n<p>7 月 3 日，NMPA 官网显示，礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究，Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报，扫描文末二维码添加小音，即可免费下载。截图来源：NMPA 官网替尔泊肽（Tirzepatide，穆峰达®）是代谢领域的重磅炸弹药物。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703153807a4ccc5af&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>重磅！礼来“替尔泊肽”又一适应症在华获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n重磅！礼来“替尔泊肽”又一适应症在华获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-03 15:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703153807a4ccc5af&s=b><strong>Insight数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7 月 3 日，NMPA 官网显示，礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究，Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报，扫描文末二维码添加小音，即可免费下载。截图来源：NMPA 官网替尔泊肽（Tirzepatide，穆峰达®）是代谢领域的重磅炸弹药物。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703153807a4ccc5af&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2361044865.SGD","symbol_name":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703153807a4ccc5af&s=b","article_id":"2548534875","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703153807a4ccc5af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548534875","pubTimestamp":1751527805,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7 月 3 日，NMPA 官网显示，礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。未来，替尔泊肽仍是有望问鼎“药王”宝座的关键选手之一。该研究旨在评估每周一次皮下注射替尔泊肽与安慰剂相比，在 469 位中重度 OSA 肥胖成年患者中的疗效和安全性。结果表明，无论患者是否接受 PAP 治疗，替尔泊肽均能显著改善中重度 OSA 肥胖患者的睡眠呼吸暂停症状。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999015978.USD":"利安颠覆性创新基金A","BK4534":"瑞士信贷持仓","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LLY":"礼来","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","SG9999014906.USD":"大华全球优质成长基金Acc USD"},"translate_title":"Heavy! Another indication of Eli Lilly's \"Tilpotide\" approved in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"7 月 3 日，NMPA 官网显示，礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究，Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报，扫描文末二维码添加小音，即可免费下载。截图来源：NMPA 官网替尔泊肽（Tirzepatide，穆峰达®）是代谢领域的重磅炸弹药物。自该药在 2022 年首次获批以来，其放量速度就势不可挡，上市次年就进入药品销售 TOP100，2024 年度更是踏入 TOP5 之列，实现 164.66 亿美元全球销售额，带动礼来市值攀升过 7000 亿美元。未来，替尔泊肽仍是有望问鼎“药王”宝座的关键选手之一。该药迄今已经在中美日欧四大主流市场获批上市，适应症由2 型糖尿病拓展到肥胖、阻塞性呼吸暂停（OSA）。在研适应症则包括心力衰竭、心血管风险、MASH、慢性肾脏病等，逐渐覆盖代谢相关疾病谱系。替尔泊肽中美日欧四大主流市场获批情况截图来自：Insight 数据库网页版据 Insight 数据库显示，礼来目前已为替尔泊肽登记启动33 项 III 期临床试验。截图来自：Insight 数据库网页版从减重领域来看，SURMOUNT-CN 研究显示，中国患者经过52 周的治疗，替尔泊肽 10 mg 和 15 mg 治疗组体重自基线的平均变化百分比分别为 -14.4% 和 -19.9%，优效于安慰剂组(-2.4%)；替尔泊肽组(10 mg，91.4%；15 mg，92.7%)达到体重减轻 ≥ 5% 的患者比例优效于安慰剂组(29.4%)。截图来自：Insight 数据库网页版从 2 型糖尿病领域看，在国内的获批基于全球关键III 期注册试验 SURPASS 1-5 及亚太地区关键 III 期注册试验 SURPASS-AP-Combo 的结果。而对于阻塞性呼吸暂停（OSA），其获批上市则是基于SURMOUNT-OSA研究数据。该研究旨在评估每周一次皮下注射替尔泊肽与安慰剂相比，在 469 位中重度 OSA 肥胖成年患者中的疗效和安全性。研究分为两部分，其中 Study 1 纳入的是未接受正压通气（PAP）治疗的患者，Study 2 则是接受并计划继续进行 PAP 治疗的患者。结果表明，无论患者是否接受 PAP 治疗，替尔泊肽均能显著改善中重度 OSA 肥胖患者的睡眠呼吸暂停症状。Study 1 结果显示，治疗 52 周时，Tirzepatide 组受试者平均 AHI 较基线降低了 27.4 次/小时（VS 安慰剂组 4.8 次/小时），达到主要终点。次要终点方面，Tirzepatide 可使平均 AHI 较基线降低 55.0%（VS 安慰剂组 5.0%）；平均体重较基线减少 18.1%（VS 安慰剂组 1.3%）。截图来自：企业官微Study 2 结果显示，在 52 周时，Tirzepatide 组受试者平均 AHI 较基线降低了 30.4 次/小时（VS 安慰剂组 6.0 次/小时）。此外，Tirzepatide 可使平均 AHI 较基线降低 62.8%（VS 安慰剂组 6.4%）以及平均体重较基线降低了 20.1%（VS 安慰剂组 2.3%）。截图来自：企业官微安全性方面，Tirzepatide 的总体安全性与此前公布的 SURMOUNT 和 SURPASS 研究结果相似，常见不良反应与胃肠道相关，严重程度一般为轻度至中度。SURMOUNT-OSA 研究结果来自：Insight 数据库网页版礼来和诺和诺德是 GLP-1 赛道的两大龙头，持续你追我赶。除替尔泊肽外，礼来在 GLP-1 赛道还布局有全球进度最快的口服 GLP-1R 激动剂Orforglipron和GLP-1R/GCGR/GIPR 三靶点激动剂Retatrutide（瑞他鲁肽），当前都在 III 期临床研发当中，首发适应症已经转向了肥胖领域。而诺和诺德则围绕司美格鲁肽布局下一众潜力管线，以IcoSema（依柯胰岛素+司美格鲁肽）和CagriSema（Cagrilintide+司美格鲁肽）为代表。仅仅是替尔泊肽和司美格鲁肽本身，在适应症开发上也各有侧重、各有其优势。礼来在 OSA 上抢先占据优势地位，诺和诺德则是抢先攻占慢性肾病领域。Insight 数据库整理了 2025 年全球新药获批上市清单（每月初更新一次，目前更新至 5 月），扫描下方二维码，回复关键词新药获批即可免费获取。封面来源：企业 Logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548534875","isCrawlerRequest":true}